Go to content
UR Home

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

Schlenk, R. F. ; Weber, D. ; Herr, W. ; Wulf, G. ; Salih, H. R. ; Derigs, H. G. ; Kuendgen, A. ; Ringhoffer, M. ; Hertenstein, B. ; Martens, U. M. ; Grießhammer, M. ; Bernhard, H. ; Krauter, J. ; Girschikofsky, M. ; Wolf, D. ; Lange, E. ; Westermann, J. ; Koller, E. ; Kremers, S. ; Wattad, M. ; Heuser, M. ; Thol, F. ; Göhring, G. ; Haase, D. ; Teleanu, V. ; Gaidzik, V. ; Benner, A. ; Döhner, K. ; Ganser, A. ; Paschka, P. ; Döhner, H.


The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were randomized to four induction schedules for two cycles: STANDARD (idarubicin, cytarabine, etoposide); and azacitidine given prior (PRIOR), concurrently (CONCURRENT), or after (AFTER) therapy with ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons